Chesapeake Urology Associates

Recent papers from Chesapeake Urology Associates

1. Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trialEuropean Journal of Cancer · 2026
2. Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trialThe Lancet Oncology · 2026
3. Advancing metastatic prostate cancer care: best practices and future directions in molecular testingProstate International · 2026
4. Testosterone suppression, safety, and adherence with relugolix in patients with metastatic prostate cancer: 6-month subgroup analysis of the OPTYX study.Journal of Clinical Oncology · 2026
5. Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United StatesClinicoEconomics and Outcomes Research · 2026
6. Empowering educators: An international virtual mentorship program for hematology/oncology medical educators.Journal of Clinical Oncology · 2026
7. Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancerTherapeutic Advances in Medical Oncology · 2026
8. Long-term outcomes with radium-223 in metastatic castration resistant prostate cancer: US patient subset of the 10-year REASSURE global study.Journal of Clinical Oncology · 2026
9. Real-world clinical outcomes among patients with localized prostate cancer (LPC) undergoing radical prostatectomy (RP).Journal of Clinical Oncology · 2026
10. Updated efficacy results from the phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).Journal of Clinical Oncology · 2026
11. Real-world comparison of prostate-specific antigen (PSA) response in metastatic castration-sensitive prostate cancer (mCSPC) patients treated with apalutamide (APA) without docetaxel vs darolutamide (DARO) without docetaxel.Journal of Clinical Oncology · 2026
12. Quality of life, adherence, and adverse events among patients with advanced prostate cancer treated with relugolix: 6-month results of the OPTYX multicenter registry.Journal of Clinical Oncology · 2026
13. Assessment of Fellowship Didactic Curricula in Hematology/Oncology: Cross-Sectional Findings From the PODCAST-HOF TrialJournal of Cancer Education · 2026
14. Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate CancerUrology · 2026
15. Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamideJournal of Comparative Effectiveness Research · 2026
16. Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone AcetateJournal of health economics and outcomes research · 2025
17. Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder CancerJournal of Clinical Oncology · 2025
18. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate CancerNew England Journal of Medicine · 2025
19. Metastatic Castration-Resistant Prostate Cancer: 14-Year Real-World Sipuleucel-T Outcomes in Urology2025
20. Parental Sexual Orientation Socialization for Sexual Minority Youth: An Empirically‐Derived Conceptual ModelJournal of Marriage and Family · 2025